Germany should back off price limits, Sanofi exec says; Takeda to stop selling 13 Pfizer meds;

@FiercePharma: China's pharma industry blames toxic capsules on super-aggressive tendering, says corner-cutting won't stop. Report | Follow @FiercePharma

>Germany should nix its rebates and price limits now that its insurers are profitable, Sanofi operations chief Hanspeter Spek told Der Tagesspiegel. Report

>Pfizer partner Takeda will stop selling 13 of the U.S.-based drugmaker's products in Japan as Pfizer takes over their marketing; the two will still work together on Enbrel. Report

>Teva's new higher-dose version of Copaxone, designed for injection only three times weekly, performed well in a new study, raising the company's hopes of prolonging sales of its big-selling drug. Report

>Antibiotic use in children and adolescents is down 7% from 2002 levels, while prescriptions for ADHD drugs have jumped, an FDA report finds. Report

>India's Piramal Healthcare is in early talks to buy the contract drugmaker Cambridge Major Laboratories for up to $200 million, the Financial Express reported. Report

>Almost half of Pradaxa patients requiring surgery were able to stop therapy for just two days to minimize bleeding, compared with 11% on rival anticoagulant warfarin, a study found. Release

> FDA keeps door open to pharmacy versions of KV's Makena. More

> Biotest prepared to exit Greece for non-payment. Story

> Cipla chief aims for more cut-rate cancer drugs. Article

Biotech News

@FierceBiotech: The Fierce team has landed in Boston. Check out our dedicated BIO2012 page. Special Coverage | Follow @FierceBiotech

@JohnCFierce: Quintiles (CRO) is expanding in China, building a regional HQ in Shanghai. Release | Follow @JohnCFierce

@RyanMFierce: Roche does an encore Alzheimer's deal with AC Immune worth up to $420M, focused on anti-Tau antibodies. More | Follow @RyanMFierce

> BIO's James Greenwood sees industry optimism returning. Report

> Roche snags another Alzheimer's antibody from AC Immune in $418M-plus deal. News

> Ambrx inks $303M 'smart bomb' development pact with Merck. More

> Infinity Pharma writes off lead drug after two more failed studies. Article

Medical Devices News

@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

> Oxford Immunotec pulls in $28M to boost TB Dx test. Story

> How can the FDA fix its device-approval process? Article

> Industry may be overstating effect of device tax. More

Biotech IT News

> Harvard IDs key human-hosted bugs with computer systems. More

> Third Rock fuels $41M launch of Bay Area biotech. Item

> Africa goes mobile to tackle drug safety woes. Story

And Finally ... China's pharmaceutical industry blamed aggressive pricing policies for the corner-cutting that led to a flood of tainted gelatin capsules. Report